Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

VACCINE AGAINST ALZHEIMER’S

In a test, a vaccine has cleared the brain protein tangles and build-ups that characterize Alzheimer’s disease.
Researchers at the University of California and the Institute for Molecular Medicine genetically engineered mice to develop the tau protein tangles and amyloid protein build-ups that accumulate among brain cells that mark the illness.
Previous vaccines had targeted one protein or the other. But new research indicates that Alzheimer’s symptoms crop up when accumulations of the two proteins interact.
The researchers paired two vaccines, each one shown to be effective against one or the other protein culprit. Then they combined the pair with a compound that made tissues more receptive to them.
In tests, the cocktail not only removed problem proteins that had accumulated but also prevented them from building up in the brains of mice engineered to develop them.
The vaccine could be in human trials as soon as 2022.
TRENDPOST: Alzheimer’s research is shifting from treatment to prevention after the repeated failures of several promising therapies. The new compound could achieve both aspects and turn Alzheimer’s into a curable and also preventable illness.

Comments are closed.